Answers are grounded in this paper and cite their sources.
The number of worldwide genomic newborn screening (gNBS) programs has rapidly expanded over the last few years, to over 50 and counting. Evidence from hundreds of thousands of screened newborns will likely be needed to determine the feasibility, acceptability, utility and cost-effectiveness of gNBS to inform potential public health implementation. However, initial published cohorts have been relatively small. Additionally, the way in which gNBS programs have reported results are inconsistent, which may hinder future meta-analyses.
No takes yet. Share an insight, caveat, or question.
Cope et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: